EMERYVILLE, Calif. & AUCKLAND, New Zealand--(BUSINESS WIRE)--Origen Therapeutics of Emeryville, California and Genavia Therapeutics of Auckland, New Zealand today announced an agreement granting Genavia access to Origen’s transgenic technology for the production of therapeutic proteins in chicken eggs. The patent-protected technology has been shown capable of producing in egg whites high-value therapeutic proteins that are currently produced by expensive cell culture manufacturing processes. Financial details of the agreement were not disclosed.
